Metipranolol-associated granulomatous anterior uveitis

Area of Science:

• Ophthalmology
• Clinical Pharmacology
• Adverse Drug Reactions

Background:

• Glaucoma management often involves topical medications.
• Ocular inflammation can be a serious side effect of ophthalmic drugs.
• Granulomatous anterior uveitis presents with specific clinical signs.

Purpose of the Study:

• To document and describe metipranolol-associated granulomatous anterior uveitis.
• To report clinical details and photographic evidence of this adverse reaction.
• To highlight the association between metipranolol use and uveitis development.

Main Methods:

• Retrospective case series analysis.
• Review of clinical records and photographic evidence.
• Correlation of uveitis episodes with metipranolol dosage and duration.

Main Results:

• Documented 56 episodes of granulomatous anterior uveitis in 15 patients using metipranolol.
• Common findings included mutton-fat keratic precipitates, flare, and cells.
• Loss of intraocular pressure control occurred in 53.6% of episodes.
• Metipranolol 0.6% was implicated in most cases.
• Fifty-one additional cases reported to the Committee on Safety of Medicines.
• Multidose metipranolol was withdrawn from UK clinical use.

Conclusions:

• Metipranolol is associated with a significant risk of granulomatous anterior uveitis.
• This adverse drug reaction can lead to compromised intraocular pressure control.
• The withdrawal of metipranolol from the UK market reflects the severity of this side effect.